Breaking News

Twitter Quarterly Profit of 2 Cents a Share Beats Estimates; Shares Surge
Tweet TWEET

OxOnc Announces Agreement With Pfizer to Develop Crizotinib as First-Line and Second-Line Treatment for Patients With ROS1

OxOnc Announces Agreement With Pfizer to Develop Crizotinib as First-Line and
Second-Line Treatment for Patients With ROS1-Positive Non-Small Cell Lung
Cancer

Pivotal Trial to be Conducted in Four Asian Countries

PRINCETON, N.J., Feb. 8, 2013 (GLOBE NEWSWIRE) -- OxOnc Development LP,
(OxOnc), today announced that it has entered into a co-development agreement
with Pfizer Inc., to conduct a pivotal clinical trial of Pfizer's crizotinib,
marketed under the trademark Xalkori®, for the treatment of patients with
advanced non-small cell lung cancer (NSCLC) harboring a ROS1 (c-ros) gene
rearrangement (ROS1-positive). ROS1 is a receptor tyrosine kinase of the
insulin receptor family.

The trial will be conducted at multiple sites in Japan, China, Taiwan and
South Korea to assess the safety and efficacy of crizotinib in patients with
ROS1-positive advanced NSCLC.Crizotinib is approved for the treatment of
patients with ALK-positive advanced NSCLC in the U.S., EU^1, Japan and other
countries. 

Under the terms of the agreement, OxOnc will provide funding and supervision
for the trial, with the goal of generating the clinical data necessary for
Pfizer to submit crizotinib for review by regulatory authorities for the
treatment of advanced ROS1-positive NSCLC in the Asian region.If approved for
this indication, OxOnc will be eligible to receive milestone payments from
Pfizer. Additional terms were not disclosed.

"We are extremely pleased to collaborate with Pfizer and to support further
clinical development of Xalkori® in NSCLC patents. It is gratifying to be
involved in co-developing this innovative targeted therapy which exemplifies
the future of oncology drug development," said Wenn Sun, Ph.D., OxOnc's
Managing Partner.

"Pfizer continues to establish innovative partnerships that extend the scale
and scope of our oncology clinical development program," said Garry Nicholson,
president and general manager, Pfizer Oncology. "Xalkori® is a breakthrough
medicine in our oncology portfolio which may hold potential for patients with
ROS1-positive advanced NSCLC.Through our collaboration with OxOnc, we hope to
explore the potential benefit that this important therapy may bring to this
subset of lung cancer patients who are in need of additional treatment
options."

About NSCLC and Crizotinib (Xalkori®):

The understanding of lung cancer is changing. What was previously believed to
be an illness largely linked to smoking is now recognized by physicians as a
complex disease with many subtypes. NSCLC comprises approximately 85 percent
of lung cancer cases.Research on the genetics of NSCLC is leading to an
evolution in lung cancer treatment paradigms.

Xalkori® is a first-in-class, small molecule inhibitor of anaplastic lymphoma
kinase (ALK), and is approved in the U.S., EU, Japan, China and other
countries to treat patients with ALK-positive advanced NSCLC. In a Phase 1
clinical trial, Xalkori® demonstrated early signs of antitumor activity in a
cohort of advanced NSCLC patients whose tumors have the ROS1 gene
rearrangement.^2 Its activity in this patient population continues to be
studied in other ongoing trials.^3

About OxOnc:

OxOnc Development LP is an oncology development company founded by
pharmaceutical development executives and oncology experts.OxOnc partners
have extensive experience in building and managing oncology research networks
in Europe and Asia and in managing global contract research organizations to
optimally design and execute clinical trials.OxOnc is funded by Orbimed
Advisors, a leading venture capital group in life sciences, with $6 billion
under management.MTS Securities, LLC acted as exclusive financial advisor to
OxOnc on this transaction.Foley & Lardner LLP and WilmerHale acted as legal
counsel in the transaction.

Forward-Looking Information Statement

This release contains forward-looking information about a potential additional
indication for crizotinib, including its potential benefits, that involves
substantial risks and uncertainties. Such risks and uncertainties include,
among other things, the uncertainties inherent in research and development;
whether and when any drug applications may be filed in any jurisdictions for
such additional indication; whether and when any such applications may be
approved by regulatory authorities, as well as their decisions regarding
labeling and other matters that could affect its availability or commercial
potential; and competitive developments.

^1 Crizotinib (Xalkori®) has received conditional marketing authorization in
the EU for the treatment of adults with previously treated ALK-positive
advanced NSCLC.

^2 ASCO Accepted Abstract #7508. Clinical activity of crizotinib in advanced
non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. Clinical
Science Symposium. Alice T. Shaw. Saturday, June 2, 2012. 8:00 AM – 8:15 AM.

^3 Clinicaltrials.gov. A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth
Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer. Available
at: http://clinicaltrials.gov/ct2/show/NCT00585195. Accessed February 1, 2013.

CONTACT: Wenn Sun, Ph.D.
         OxOnc Development LLC
         T: 609.228.5757 ext: 102
         F: 609.935.0918
         Email: Info@oxfordoncology.com